Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rexmyelocel-T for critical limb ischemia in adults with diabetes mellitus
2016-000240-34Phase 3Recruiting
- Sponsor
- Ixaka
- Start
- Apr 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing Rexmyelocel-T with Placebo (2 arms). Primary endpoint: Clinically relevant response in Rutherford Category. Started Apr 2016; status: recruiting.
02
Drugs
rexmyelocel-T
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2016-000240-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000240-34.